Natco Pharma jumps 4% on filing generic version of oncology drug in US

Shares of Natco Pharma jumped 4.5 per cent to Rs 549 per share in Monday's intra-day trade, after the company filed a generic version of an oncology drug in the US markets. In comparison, the S&P BSE Sensex dropped 0.6 per cent to hit day's low of 60,283 levels.
 

The drug major filed an abbreviated new drug application (ANDA) for generic versions of Olaparib tablets - 100 mg and 150 mg with the US Food and Drug Administration (USFDA). Olaparib is primarily used to treat ovarian, breast, pancreatic, and prostate cancer.
 

Since Olaparib tablets are marketed in the US by